Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human TNF receptor II-Fc fusion protein in rheumatoid arthritis
CTR20131919Phase 3Completed
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Jan 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept in rheumatoid arthritis (RA), sponsored by Shanghai Celgen Biopharma. Started Jan 2015; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20131919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131919.